JAMA Derm

Vagus nerve stimulation shows promise for rosacea-related facial redness

October 10, 2025

Transcutaneous auricular vagus nerve stimulation (taVNS) may offer a novel, nonpharmacologic treatment option for erythematotelangiectatic rosacea (ETR) by modulating neurovascular inflammation. Given its safety profile and ease of use, taVNS could be a valuable adjunct or alternative to current therapies, particularly for patients seeking non-topical or drug-free interventions.

Study details: This randomized, sham-controlled trial evaluated the efficacy of taVNS in adults with ETR, a subtype characterized by persistent facial erythema and visible blood vessels. Participants received either active taVNS or sham stimulation for 20 minutes daily over 8 weeks. Primary endpoint: change in Clinician’s Erythema Assessment (CEA) score.

Results: Patients in the taVNS group showed a significantly greater reduction in CEA scores compared with the sham group at week 8. Improvements were also observed in patient-reported outcomes, including the Flushing Symptom Questionnaire and Dermatology Life Quality Index. No serious adverse events were reported, and taVNS was well tolerated.

Source:

Li J, et al. (2025, October 8). JAMA Dermatol. Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Erythematotelangiectatic Rosacea: A Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/41060641/